1. Home
  2. EAD vs TECX Comparison

EAD vs TECX Comparison

Compare EAD & TECX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Allspring Income Opportunities Fund

EAD

Allspring Income Opportunities Fund

HOLD

Current Price

$6.85

Market Cap

405.4M

Sector

Finance

ML Signal

HOLD

Logo Tectonic Therapeutic Inc.

TECX

Tectonic Therapeutic Inc.

HOLD

Current Price

$24.37

Market Cap

366.8M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
EAD
TECX
Founded
2003
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
405.4M
366.8M
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
EAD
TECX
Price
$6.85
$24.37
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$80.40
AVG Volume (30 Days)
178.9K
284.0K
Earning Date
01-01-0001
03-19-2026
Dividend Yield
8.91%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.69
$13.70
52 Week High
$6.81
$47.35

Technical Indicators

Market Signals
Indicator
EAD
TECX
Relative Strength Index (RSI) 54.73 64.77
Support Level $6.83 $21.33
Resistance Level $6.90 $24.53
Average True Range (ATR) 0.04 1.81
MACD 0.00 0.43
Stochastic Oscillator 69.23 71.46

Price Performance

Historical Comparison
EAD
TECX

About EAD Allspring Income Opportunities Fund

Allspring Income Opportunities Fund is a diversified closed-end management investment company. Its products and services are mutual funds, closed-end funds, managed accounts services, and variable trust funds. The fund's objective is a high level of current income and capital appreciation. Its portfolio of investments is Commercial services, healthcare services, Food, Pharmaceuticals, Energy, Oil & gas, Pipelines, Diversified financial services, and Others.

About TECX Tectonic Therapeutic Inc.

Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. Company focus on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.

Share on Social Networks: